Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer-Reference-Cited by-同舟云学术

Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer

Published:2021-10-12 Issue:1 Volume:38 Page:91-99
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Winfree Katherine B.¹^ORCID,Sheffield Kristin M.¹^ORCID,Cui Zhanglin Lin¹^ORCID,Sugihara Tomoko²,Feliciano Josephine³

Affiliation:

1. Eli Lilly and Company, Indianapolis, IN, USA

2. Syneos Health, Morrisville, NC, USA

3. Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1983530

Reference30 articles.

1. American Cancer Society. Lung and bronchus [Internet]. Farmingham (MA): ACS; 2020 [cited 2021 Feb 10]. Available from: http://cancerstatisticscenter.cancer.org/#/cancer-site/Lung%20and%20bronchus

2. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

3. American Society for Clinical Oncology. Lung cancer - non-small cell: statistics [Internet]. Alexandria (VA): ASCO; 2020 [cited 2021 Feb 11]. Available from: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics#:∼:text=NSCLC%20is%20the%20most%20common,be%20diagnosed%20with%20lung%20cancer

4. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC;Oncology and Therapy;2024-07-30

2. Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib;Current Oncology;2024-04-26

3. Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors;Frontiers in Oncology;2024-04-18

4. To establish a prognostic model of epidermal growth factor receptor mutated non-small cell lung cancer patients based on Least Absolute Shrinkage and Selection Operator regression;European Journal of Cancer Prevention;2023-11-28

5. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study;Advances in Therapy;2023-05-23